2192619
Last Update Posted: 2024-02-23
Recruiting
All Genders accepted | 18 Years + |
500 Estimated Participants | No Expanded Access |
Observational Study | Does not accept healthy volunteers |
National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
The registry aims to document epidemiologic data, treatment and long-term outcome as well as quality of life of patients with APL. Additionally, a biobanking project for further translational studies is integrated.
Prospective population-based non-interventional and non-randomized multicenter registry.
* collection of epidemiological data for APL: age distribution, prognostic factors, distribution of subgroups, incidence * documentation of efficacy and safety of the first line and salvage therapy in APL including * documentation of minimal residual disease (MRD) * correlation of clinical outcomes with chosen therapy * collection and evaluation of quality of life * validation of published prognostic factors / new potential prognostic factors * acquisition of bone marrow, peripheral blood and buccal swab samples for biobanking and translational studies under the umbrella of the specific study-group biobanking concepts
Eligibility
Relevant conditions:
Newly-diagnosed APL (de Novo or Therapy-related)
Relapsed APL
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Uwe Platzbecker, Prof. Dr.
Uwe.Platzbecker@medizin.uni-leipzig.de
+49 351 458 3192
Michaela Weier
michaela.weier@ukdd.de
+49 351 458 3192
Data sourced from ClinicalTrials.gov